Information Provided By:
Fly News Breaks for June 20, 2018
Jun 20, 2018 | 07:24 EDT
Cantor Fitzgerald analyst Mara Goldstein believes Array BioPharma's combination of binimetinib/encorafenib has the "potential to be best-in-class and take a market-leader position." The FDA action date is June 30. Further, the analyst sees opportunity in BRAF+ CRC based on the safety lead-in portion of the Beacon study, which she believes could expand the potential market, with updated results to be presented on June 23. Goldstein thinks Array shares "could have further room to advance" and keeps an Overweight rating on the name with a $24 price target.
News For ARRY From the Last 2 Days
There are no results for your query ARRY